Strategic Blueprint LLC Grows Stock Holdings in Stryker Co. (NYSE:SYK)

Strategic Blueprint LLC grew its holdings in Stryker Co. (NYSE:SYK) by 2.7% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,465 shares of the medical technology company’s stock after buying an additional 39 shares during the period. Strategic Blueprint LLC’s holdings in Stryker were worth $527,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently made changes to their positions in the company. Dunhill Financial LLC grew its position in Stryker by 94.9% in the third quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock worth $27,000 after acquiring an additional 37 shares in the last quarter. Darwin Wealth Management LLC purchased a new position in shares of Stryker in the 3rd quarter worth approximately $36,000. HBW Advisory Services LLC bought a new position in shares of Stryker during the 3rd quarter valued at approximately $42,000. Hara Capital LLC purchased a new stake in Stryker during the 3rd quarter valued at $42,000. Finally, Grove Bank & Trust lifted its position in Stryker by 84.8% in the third quarter. Grove Bank & Trust now owns 122 shares of the medical technology company’s stock worth $44,000 after buying an additional 56 shares during the last quarter. 77.09% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

SYK has been the topic of several recent analyst reports. The Goldman Sachs Group increased their target price on shares of Stryker from $384.00 to $427.00 and gave the company a “neutral” rating in a research note on Thursday. Barclays increased their price objective on shares of Stryker from $402.00 to $418.00 and gave the stock an “overweight” rating in a research report on Thursday, October 31st. UBS Group upped their target price on Stryker from $366.00 to $370.00 and gave the company a “neutral” rating in a research note on Wednesday, October 30th. Piper Sandler reissued an “overweight” rating and set a $420.00 price target (up from $380.00) on shares of Stryker in a research note on Wednesday, October 30th. Finally, StockNews.com downgraded Stryker from a “buy” rating to a “hold” rating in a research report on Thursday. Five investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. Based on data from MarketBeat, Stryker has a consensus rating of “Moderate Buy” and an average price target of $419.37.

Stryker Stock Up 0.1 %

Stryker stock opened at $390.90 on Friday. Stryker Co. has a twelve month low of $314.93 and a twelve month high of $406.19. The business has a fifty day moving average of $376.56 and a two-hundred day moving average of $362.38. The firm has a market cap of $149.02 billion, a P/E ratio of 50.37, a P/E/G ratio of 2.68 and a beta of 0.95. The company has a quick ratio of 1.22, a current ratio of 1.91 and a debt-to-equity ratio of 0.66.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, beating analysts’ consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.86% and a net margin of 13.25%. During the same quarter in the prior year, the company earned $3.46 EPS. On average, analysts forecast that Stryker Co. will post 13.53 earnings per share for the current fiscal year.

Stryker Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, January 31st. Investors of record on Tuesday, December 31st were given a dividend of $0.84 per share. This is a boost from Stryker’s previous quarterly dividend of $0.80. The ex-dividend date was Tuesday, December 31st. This represents a $3.36 dividend on an annualized basis and a yield of 0.86%. Stryker’s dividend payout ratio is presently 43.30%.

Insider Buying and Selling at Stryker

In other Stryker news, CEO Kevin Lobo sold 57,313 shares of the firm’s stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $368.70, for a total value of $21,131,303.10. Following the completion of the sale, the chief executive officer now owns 100,027 shares of the company’s stock, valued at approximately $36,879,954.90. This trade represents a 36.43 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 5.90% of the stock is owned by insiders.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.